Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open Label Dose Escalation Study to Investigate the Safety and Tolerability of Acadesine in Patients With B-cell Chronic Lymphocytic Leukemia

NCT00559624 is registered in ClinicalTrials.gov with Advancell - Advanced In Vitro Cell Technologies, S.A. as lead sponsor.

NCT NCT00559624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00559624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open Label Dose Escalation Study to Investigate the Safety and Tolerability of Acadesine in Patients With B-cell Chronic Lymphocytic Leukemia
Lead sponsor
Advancell - Advanced In Vitro Cell Technologies, S.A.
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2007
Completion date
December 31, 2010
Enrollment
40 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, b-cell, chronic